SCHEMBL1389820

SCHEMBL1389820

CCC(C)CC(C(=O)O)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.56
SLC1A2 P43004 2/20 0.56
SLC1A1 P43005 2/20 0.56
MAPT P10636 1/20 0.35
ACE P12821 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SLC7A5 Q01650 2/20 0.34
RNPEP Q9H4A4 1/20 0.34
TP53 P04637 1/20 0.33
ACE2 Q9BYF1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14408582 0.80 SLC1A3 (0.36) SLC1A3SLC1A2SLC1A1MAPTACE
SCHEMBL112582 0.79
SCHEMBL12879790 0.79
SCHEMBL13711834 0.79
SCHEMBL27776026 0.79 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1ACETDP1
SCHEMBL21883848 0.79 SLC1A3 (0.39) SLC1A3SLC1A2SLC1A1
SCHEMBL11022612 0.79 SLC1A3 (0.54) SLC1A3SLC1A2SLC1A1TDP1SLC7A5
SCHEMBL9357548 0.77 SLC1A3 (0.39) SLC1A3SLC1A2SLC1A1MAPTTDP1
SCHEMBL1682325 0.77 SLC1A3 (0.39) SLC1A3SLC1A2SLC1A1MAPTTDP1
SCHEMBL2717757 0.77 SLC1A3 (0.62) SLC1A3SLC1A2SLC1A1TDP1SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255208-B1 CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS VOYAGE FOODS INC (US) 2024-12-25 EP claimed
EP-3930472-B1 COFFEE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS VOYAGE FOODS INC (US) 2024-09-11 EP claimed
EP-2854750-B1 TRPA1 ANTAGONISTS FOR REDUCING NEGATIVE SENSATIONS CAUSED BY HYDROGEN PEROXIDE PROCTER & GAMBLE (US) 2019-10-02 EP claimed
EP-1673332-B1 HYDROFORMYLATION OF BUTENES COMPRISING ISOBUTYLENE EXXONMOBIL CHEM PATENTS INC (US) 2015-06-17 EP claimed
US-20120253059-A1 Hydroformylation Of Butenes EXXONMOBIL CHEMICAL PATENTS INC. 2012-10-04 US claimed
US-8178730-B2 Processes related to the hydroformylation of butenes EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-05-15 US claimed
US-20120010426-A1 Processes Related to the Hydroformylation of Butenes EXXONMOBIL CHEMICAL PATENTS INC. 2012-01-12 US claimed
EP-1716159-B1 BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS MOMENTIVE PERFORMANCE MAT INC (US) 2011-07-13 EP claimed
US-20110137071-A1 Processes Related To The Hydroformylation Of Butenes EXXONMOBIL CHEMICAL PATENTS INC. 2011-06-09 US claimed
CN-100526280-C Hydroformylation of isobutene-containing butenes EXXONMOBIL CHEM PATENTS INC (US) 2009-08-12 CN claimed
WO-2008084046-A1 PLASTICIZERS FOR POLYVINYL ACETALS AND POLYSULFIDES BASF SE (DE) 2008-07-17 WO claimed
EP-1697386-B1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GEN ELECTRIC (US) 2007-10-10 EP claimed
US-20070112220-A1 Hydroformylation of butenes comprising isobutylene EXXONMOBIL CHEMICAL PATENTS INC. 2007-05-17 US claimed
CN-1856460-A Hydroformylation of isobutene-containing butenes EXXONMOBIL CHEM PATENTS INC (US) 2006-11-01 CN claimed
EP-1673332-A1 HYDROFORMYLATION OF BUTENES COMPRISING ISOBUTYLENE ExxonMobil Chemical Patents Inc. (US) 2006-06-28 EP claimed
WO-2005028407-A1 HYDROFORMYLATION OF BUTENES COMPRISING ISOBUTYLENE EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-03-31 WO claimed
EP-2145042-B2 TEXTILE SCENTING HENKEL AG & CO KGAA (DE) 2021-10-06 EP disclosed
EP-2145042-B1 TEXTILE SCENTING HENKEL AG & CO KGAA (DE) 2018-01-17 EP disclosed
EP-1673332-A1 HYDROFORMYLATION OF BUTENES COMPRISING ISOBUTYLENE ExxonMobil Chemical Patents Inc. (US) 2006-06-28 EP disclosed
WO-2005028407-A1 HYDROFORMYLATION OF BUTENES COMPRISING ISOBUTYLENE EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120253059-A1 Hydroformylation Of Butenes HMOX2, BBOX1, HMOX1 SLC1A3 2500/4885SLC1A2 2092/4885SLC1A1 2642/4885
US-20120010426-A1 Processes Related to the Hydroformylation of Butenes GRHPR, BLVRB, DHPS SLC1A3 3129/4885SLC1A2 2508/4885SLC1A1 3211/4885
US-20070112220-A1 Hydroformylation of butenes comprising isobutylene HMOX2, BBOX1, HMOX1 SLC1A3 2898/4885SLC1A2 2183/4885SLC1A1 3032/4885
US-20110137071-A1 Processes Related To The Hydroformylation Of Butenes GRHPR, BLVRB, DHPS SLC1A3 3129/4885SLC1A2 2508/4885SLC1A1 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.